Trinomab raises $13.5M cornerstone round for human antibody drugs

What's the deal? Trinomab, a clinical-stage biopharmaceutical company, has raised 91,080,000 CNY (about $13.5 million) in a cornerstone round, according to a filing announced in July 2026.

What's the endgame? The company develops original natural fully human monoclonal antibody drugs. Its core technology is HitmAb®, an integrated research platform for such antibodies.

Why does it matter? Trinomab targets treatments for infectious diseases, autoimmune diseases, malignant tumours, and other conditions. It aims to build a portfolio of proprietary, highly differentiated, and effective drugs.

The signal: A cornerstone round for a clinical-stage antibody developer points to continued investor appetite for China's homegrown biotech platforms betting on differentiated drug pipelines.

Read more: IT桅子 (ITjuzi)

Image credit: Centers for Disease Control and Prevention